Item 5.02    Departure of Directors or Certain Officers; Election of Directors;
             Appointment of Certain Officers; Compensatory Arrangements of
             Certain Officers

On March 16, 2021 (the "Effective Date"), the Board of Directors (the "Board") of Talis Biomedical Corporation (the "Company") increased the authorized size of the Board from eight (8) to nine (9) members, creating a vacancy on the Board.

On the Effective Date, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Jeryl L. Hilleman to fill the vacant Board seat and to serve as Class III director of the Board with an initial term expiring at the Company's 2024 Annual Meeting of Stockholders. Ms. Hilleman was also appointed as chairperson of the Audit Committee of the Board.

There are no arrangements or understandings between Ms. Hilleman and any other persons pursuant to which she was selected as a director of the Company. The Board has determined that Ms. Hilleman is independent under applicable U.S. Securities and Exchange Commission requirements and Nasdaq listing standards. There is no transaction involving Ms. Hilleman that requires disclosure under Item 404(a) of Regulation S-K. As of the Effective Date, Ms. Hilleman will participate in the Company's Non-Employee Director Compensation Policy pursuant to which she will receive cash compensation and an option grant for her service on the Board and the Audit Committee of the Board. The Company will also enter into its standard form of indemnification agreement with Ms. Hilleman.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses